Dasatinib-related alveolar pneumonia responsive to corticosteroids

被引：24

作者：

Radaelli, F.

Bramanti, S.

Fantini, N. N.

Fabio, G.

Greco, I.

Lambertenghi-Deliliers, G.

机构：

[1] Fdn Osped Maggiore Policlin, Dept Hematol & Oncol, I-20122 Milan, Italy

[2] Fdn Osped Maggiore Policlin, Dept Internal Med, I-20122 Milan, Italy

[3] Univ Milan, I-20122 Milan, Italy

来源：

LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 06期

关键词：

D O I：

10.1080/10428190600555868

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1180 / 1181

页数：2

共 10 条

[1] Hypersensitivity pneumonitis related to imatinib mesylate [J].

Bergeron, A ;

Bergot, E ;

Vilela, G ;

Ades, L ;

Devergie, A ;

Espérou, H ;

Socié, G ;

Calvo, F ;

Gluckman, E ;

Ribaud, P ;

Rousselot, P ;

Tazi, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4271-4272

[2] BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 [J].

Donato, NJ ;

Wu, JY ;

Stapley, J ;

Gallick, G ;

Lin, H ;

Arlinghaus, R ;

Talpaz, M .

BLOOD, 2003, 101 (02) :690-698

[3] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[4] Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms [J].

Grimison, P ;

Goldstein, D ;

Schneeweiss, J ;

Murray, N .

INTERNAL MEDICINE JOURNAL, 2005, 35 (02) :136-137

[5]

Isshiki Ikuko, 2004, Br J Haematol, V125, P420, DOI 10.1111/j.1365-2141.2004.04833.x

[6] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[7] High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia [J].

Kantarjian, H ;

Talpaz, M ;

O'Brien, SS ;

Garcia-Manero, G ;

Verstovsek, S ;

Giles, F ;

Rios, MB ;

Shan, JQ ;

Letvak, L ;

Thomas, D ;

Faderl, S ;

Ferrajoli, A ;

Cortes, J .

BLOOD, 2004, 103 (08) :2873-2878

[8]

Kantarjian HM, 2002, CLIN CANCER RES, V8, P2177

[9] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[10] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

← 1 →